Molecular Partners AG (MOLN) stock
MOLNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 20-F on Mar 12, 2026Score 1/30
$2.86+0.16 (+5.98%)
Close on Nov 17, 2026Market cap $115.47MP/E –Yield –
Molecular Partners cash
Cash and short-term investments held at the end of each period.
Molecular Partners's cash was CHF 67.93M at Jun 30, 2026. For fiscal 2025 it was CHF 82.65M, up 29.4% from the year before. The highest annual figure on record is CHF 133.72M in fiscal 2020.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | CHF 82.65M | +29.4% |
| FY2024 | Dec 31, 2024 | CHF 63.87M | -5.1% |
| FY2023 | Dec 31, 2023 | CHF 67.31M | -23.5% |
| FY2022 | Dec 31, 2022 | CHF 87.95M | +22.5% |
| FY2021 | Dec 31, 2021 | CHF 71.81M | -46.3% |
| FY2020 | Dec 31, 2020 | CHF 133.72M | +76.6% |
| FY2019 | Dec 31, 2019 | CHF 75.71M | -23.5% |
| FY2018 | Dec 31, 2018 | CHF 98.96M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | CHF 67.93M | +6.0% |
| Q4 FY2025 | Dec 31, 2025 | CHF 82.65M | +22.8% |
| Q2 FY2025 | Jun 30, 2025 | CHF 81.98M | +29.6% |
| Q4 FY2024 | Dec 31, 2024 | CHF 63.87M | -27.4% |
| Q2 FY2024 | Jun 30, 2024 | CHF 64.06M | -44.3% |
| Q4 FY2023 | Dec 31, 2023 | CHF 67.31M | -6.3% |
| Q2 FY2023 | Jun 30, 2023 | CHF 63.24M | -50.0% |
| Q4 FY2022 | Dec 31, 2022 | CHF 87.95M | -34.2% |
| Q2 FY2022 | Jun 30, 2022 | CHF 114.94M | +51.8% |
| Q4 FY2021 | Dec 31, 2021 | CHF 71.81M | -27.4% |
| Q2 FY2021 | Jun 30, 2021 | CHF 126.57M | – |
| Q4 FY2020 | Dec 31, 2020 | CHF 133.72M | – |
| Q4 FY2019 | Dec 31, 2019 | CHF 75.71M | – |
| Q4 FY2018 | Dec 31, 2018 | CHF 98.96M | – |
See a number that looks wrong?